Khaw Rachel A, Nevins Edward J, Phillips Alexander W
Northern Oesophagogastric Unit, Royal Victoria Infirmary, Newcastle Upon Tyne, NE1 4LP, UK.
Newcastle University, Newcastle upon Tyne, UK.
J Gastrointest Surg. 2022 Aug;26(8):1781-1790. doi: 10.1007/s11605-022-05323-y. Epub 2022 Apr 28.
Survival following oesophagectomy for cancer is improving, resulting in increased focus on quality of life and survivorship. Malabsorption syndrome is multifactorial and includes exocrine pancreatic insufficiency (EPI), small intestinal bacterial overgrowth (SIBO) and bile acid malabsorption (BAM). The aim of this study was to evaluate the reported incidence and management of malabsorption syndromes post-oesophagectomy.
A systematic search of PubMed, EMBASE, MEDLINE, Scopus and the Cochrane Library evaluating incidence, diagnosis and management of malabsorption was performed for studies published until December 2021.
Of 464 identified studies, eight studies (n = 7 non-randomised longitudinal studies) were included where patients were identified with malnutrition following oesophagectomy. Studies included a combined sample of 328 (range 7-63) patients. Malabsorption syndromes including EPI, SIBO and BAM occurred in 15.9-100%, 37.8-100% and 3.33-100% over 21 days-60 months, 1-24 months and 1-24 months respectively. There was no consensus definition for EPI, SIBO or BAM, and there was variation in diagnostic methods. Diagnostic criteria varied from clinical (gastrointestinal symptoms or weight loss), or biochemical (faecal elastase, hydrogen breath test and Selenium-75-labelled synthetic bile acid measurements). Treatment modalities using pancreatic enzyme replacement, rifaximin or colesevelam showed improvement in symptoms and weight in all studies, where investigated.
Malabsorption syndromes following oesophagectomy are under-recognised, and thus under-reported. The resultant gastrointestinal symptoms may have a negative effect on post-operative quality of life. Current literature suggests benefit with outlined therapies; however, greater understanding of these conditions, their diagnosis and management is required to further understand which patients will benefit from treatment.
食管癌切除术后的生存率正在提高,这使得人们越来越关注生活质量和生存情况。吸收不良综合征是多因素导致的,包括外分泌性胰腺功能不全(EPI)、小肠细菌过度生长(SIBO)和胆汁酸吸收不良(BAM)。本研究的目的是评估食管癌切除术后吸收不良综合征的报告发病率及管理情况。
对PubMed、EMBASE、MEDLINE、Scopus和Cochrane图书馆进行系统检索,以评估截至2021年12月发表的关于吸收不良发病率、诊断和管理的研究。
在464项已识别的研究中,纳入了8项研究(n = 7项非随机纵向研究),这些研究中的患者在食管癌切除术后被诊断为营养不良。研究纳入的患者样本总数为328例(范围7 - 63例)。在21天至60个月、1至24个月和1至24个月期间,EPI、SIBO和BAM等吸收不良综合征的发生率分别为15.9% - 100%、37.8% - 100%和3.33% - 100%。对于EPI、SIBO或BAM没有统一的定义,诊断方法也存在差异。诊断标准从临床(胃肠道症状或体重减轻)到生化(粪便弹性蛋白酶、氢呼气试验和硒-75标记的合成胆汁酸测量)各不相同。在所有进行了相关研究的案例中,使用胰酶替代、利福昔明或考来维仑的治疗方式均显示症状和体重有所改善。
食管癌切除术后的吸收不良综合征未得到充分认识,因此报告不足。由此产生的胃肠道症状可能会对术后生活质量产生负面影响。当前文献表明所概述的治疗方法有益;然而,需要对这些病症、其诊断和管理有更深入的了解,以进一步明确哪些患者将从治疗中获益。